

Improved fluorescent CRISPR fusion proteins allow for enrichment of edited cells by fluorescence activated cell sorting



Steve E. Glenn*, Michael A. Collingwood, Christopher A. Vakulskas, Sarah F. Beaudoin, Nicole M. Bode, and Mark A. Behlke
Integrated DNA Technologies, Coralville, IA, USA

* Corresponding author: sglenn@idtdna.com

Abstract

It is often desirable to visualize CRISPR enzymes in live cells as a means to verify efficient delivery of CRISPR reagents. The most common method to accomplish this goal with protein cargo is to make an in-frame fusion to fluorescent proteins such as GFP or RFP. Here we present an improved set of CRISPR reagents that have been carefully fine-tuned to allow visualization in live cells while still retain near-wildtype levels of on-target activity. We demonstrate that fluorescent CRISPR enzyme fusion proteins and fluorescently labeled tracrRNAs can be used in combination with fluorescence-activated cell sorting to achieve levels of editing greater than with unlabeled CRISPR enzymes. We expect that these reagents will be a valuable resource in research.

IDT fluorescent CRISPR proteins maintain high on-target activity




Figure 1. IDT fluorescent CRISPR proteins maintain high on-target activity across multiple guides.

A. Alt-R™ CRISPR-Cas9 sgRNAs were designed to target NGG PAM sites within the human *HPRT* gene. Guides were complexed with Alt-R *S.p.* Cas9 Nuclease V3, Cas9-GFP, or Cas9-RFP to form ribonucleoproteins (RNPs). RNPs were then delivered into HEK293 cells using the Lonza 96 well shuttle Nucleofector™ at a concentration of 2.0 μM. After 48 hrs, genomic DNA was isolated (QuickExtract™ solution, Epicenter), and editing was assessed by T7E1 mismatch endonuclease assay. **B.** Alt-R CRISPR-Cpf1 crRNAs were designed to target TTTV PAM sites within the human *HPRT* gene. Guides were complexed with either Alt-R *A.s.* Cas12a (Cpf1) *Ultra* or *A.s.* Cas12a-GFP to form RNPs. RNP delivery and editing analysis were conducted as in (A), with the exception that RNPs were delivered at a suboptimal dose of 50 nM to achieve a range of editing across the targeted sites. Error bars represent SD, N=3 replicates.

Enrichment of edited cells by FACS




Figure 2. Fluorescent CRISPR proteins can be used to enrich for edited cells by fluorescence activated cell sorting. **A.** Alt-R CRISPR-Cpf1 crRNAs were designed to target TTTN PAM sites throughout the human genome. Guides were complexed with either Alt-R *A.s.* Cas12a (Cpf1) *Ultra*, or *A.s.* Cas12a-GFP, to form RNPs. RNPs were delivered into HEK293 cells using Lipofectamine™ RNAiMAX at 10 nM final concentration. After ~18 hrs, cells were sorted using a Becton Dickinson Aria II cell sorter into three subpopulations, GFP High: top 20%, Medium: 80–60%, and Low: Bottom 60% of cells based on GFP signal. Cells were then re-plated and genomic DNA was isolated after 48–72 hrs. Editing was analyzed by NGS. **B.** Alt-R CRISPR-Cas9 sgRNAs were designed to target NGG PAM sites throughout the human genome. Guides were complexed with either Cas9-GFP or Alt-R Cas9 V3. RNP delivery, cell sorting and editing analysis were conducted as in (A). **C.** Cas9 RNP was prepared as in (B) and delivered into HEK293 cells using a Lonza 96 well shuttle Nucleofector™ at 2.0 μM concentration. Cells were sorted and analyzed as in (A). N=1 run/sample.

Cas9-GFP allows visualization of delivery




Figure 3. Use of Cas9-GFP is most beneficial when the delivery of RNP is uneven across cells.

A. RNPs consisting of either Cas9-GFP or Alt-R Cas9 V3 complexed with Alt-R CRISPR-Cas9 sgRNAs targeting two sites in the *HPRT* gene were delivered into HEK293 cells using either Lipofectamine™ RNAiMAX at 10 nM RNP or using the Lonza Nucleofector™ system at 2 μM RNP. The graphs show the GFP signal versus cell count when sorting cells that had Cas9-GFP delivered using either lipofection or Nucleofection™ compared to Cas9 V3 delivered by Nucleofection™ as a control. **B.** The graph shows the total editing measured by NGS in either unsorted cells or the top 20% of cells based on GFP signal from (A). Cells were sorted and editing was analyzed as in Figure 2. **C.** Confocal images of HEK293 cells taken ~18 hours after delivery of either Cas9-GFP or Alt-R Cas9 V3 protein complexed with Alt-R CRISPR-Cas9 sgRNA delivered by Nucleofection™ at 2 μM RNP. Prior to imaging, live cells were incubated with Hoechst 33342 and wheat germ agglutinin (WGA)–Alexa Fluor™ 647 with prior and subsequent PBS wash steps and imaged in complete media in a Lab-Tek II #1.5 Chambered Coverglass using a Leica SP8 confocal microscope. N=1.

IDT fluorescent Cas9 is comparable to that of other vendors




Figure 4. Editing activity of IDT Cas9-GFP is comparable to that of other vendors.

A. Alt-R CRISPR-Cas9 sgRNAs targeting sites within the *HPRT* gene were complexed with IDT or Vendor A Cas9-GFP to form RNPs. RNPs were then delivered into HEK293 cells using the Lonza 96 well shuttle Nucleofector™ at a suboptimal concentration of 0.25 μM RNP. After 48 hrs, genomic DNA was isolated and editing was assessed by T7E1 mismatch endonuclease assay. Error bars represent SD, N=3 replicates. **B.** Alt-R CRISPR-Cas9 sgRNAs targeting two sites with the human *HPRT* gene were complexed with IDT, Vendor A, or Vendor B Cas9-GFP to form RNPs. RNPs were delivered into HEK293 cells using Lipofectamine™ RNAiMAX at a suboptimal dose of 1 nM RNP. Cell sorting and editing were analyzed as in Figure 2 (N=1).

IDT offers a variety of labeled CRISPR products




Figure 5. IDT Cas9-GFP and fluorescent-labeled CRISPR-Cas9 tracrRNAs offer a variety of options that allow for enrichment of edited cells by fluorescence signal. Alt-R crRNA XT was duplexed with either unlabeled, or ATTO™ labeled, tracrRNA and complexed with either Cas9-GFP or Alt-R Cas9 V3 and delivered into HEK293 cells using Lipofectamine™ RNAiMAX at 10 nM RNP. The graph shows total editing measured by NGS in cells that were sorted and analyzed as in Figure 2. N=1 run/sample.

For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

© 2021 Integrated DNA Technologies, Inc. All rights reserved. Alt-R is a trademark of Integrated DNA Technologies, Inc., and is registered in the USA. All other marks are the property of their respective owners. For specific trademark and licensing information, see www.idtdna.com/trademarks.